OPKO Health Investor Presentation — November 2020

Document content

NASDAQ: OPKForward Looking Statements

2 November 2020 |This presentation contains “forward -looking statements,” asthatterm isdefined under thePrivate Securities Litigation Reform Actof1995 (PSLRA), which statements may beidentified by

words such as“expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” and other words ofsimilar meaning, including statements

regarding expected financial performance andexpectations regarding themarket forandsales ofourproducts, expectations about COVID -19testing, thedemand fortesting, ourcapacity for

testing andexpected turnaround time, theimpact ofCOVID -19onallofourbusinesses, positively andnegatively, ourability toexpand ourcapacity should there beadditional demand, the

availability ofresources, including labor, equipment andsupplies, tomeet demand fortesting andthepotential impact onusshould these resources beconstrained, whether ourturnaround

time willbeasexpected orourperformance quality decline, ourproduct development efforts andtheexpected benefits ofourproducts, ourestimated revenues andfinancial projections,

including expected Rayaldee and BioReference revenues, whether wewillmaintain profitability orcontinue growth atBioReference, whether prescriptions forRayaldee willstabilize or

increase, expected milestones androyalties from theoutlicense ofourproducts, theoutcome ofourclinical trials andvalidation studies andthatsuch outcomes willsupport marketing approval

orcommercialization, theexpected market penetration andsizeofthemarket forourproducts, ourability tosuccessfully commercialize ourproduct candidates such ashGH-CTP, Factor VII-

CTP, andourrare disease product candidates, whether Rayaldee willraise serum total 25-hydroxyvitamin D(25D)more effectively than anyover-the-counter (OTC) orprescription (Rx)

products currently marketed without theriskofhypercalcemia, ourability todevelop Rayaldee fornew indications including stage 5CKD, andthetimeline fordoing so,whether theclinical data

forhGH-CTP willsupport submission ofaBiologics License Application (BLA), thetiming ofsuch submission, andapproval forhGH-CTP inadults andpediatric patients, whether wewillbe

required tomake anychanges toourdevelopment plans forhGH-CTP andincrease ourexpenditures, expectations regarding patent coverage, theexpected timing forcommencing, enrolling,

completing andannouncing results forourclinical trials, thetiming forrelease oftrialdata andseeking andobtaining FDA andEuropean regulatory approvals aswell asreimbursement

coverage forourproducts .These forward -looking statements areonly predictions and reflect ourviews asofthedate they were made, and weundertake noobligation toupdate such